Table 1

Baseline characteristics of patients starting second-generation sulfonylureas

CharacteristicGlyburide (n = 3,413)Other second-generation sulfonylureas (n = 49,187)Standardized difference
Male sex2,265 (66.4)36,044 (73.3)0.15
Age (years)64.0 (11.9)64.0 (12.5)0.01
BMI (kg/m2)
 Median (IQR)28.1 (25.0–31.3)29.2 (26.0–33.2)0.24
 <25628 (18.4)8,227 (16.7)0.04
 25–301,059 (31.0)16,791 (34.1)0.07
 ≥30873 (25.6)20,291 (41.3)0.34
 Unknown853 (25.0)3,878 (7.9)0.47
Smoking
 Ever1,288 (37.7)28,147 (57.2)0.40
 Never1,398 (41.0)18,469 (37.6)0.07
 Unknown727 (21.3)2,571 (5.2)0.49
Excessive alcohol use202 (5.9)5,758 (11.7)0.20
HbA1c (%) [mmol/mol]
 Median (%; mmol/mol) (IQR) 8.7; 71.6 (7.5–10.4; 58.5–90.2)8.5; 69.4 (7.6–10.0; 59.6–85.8)0.05
 ≤7 [53]180 (5.3)3,824 (7.8)0.10
 7.1–8.0 [54–64]220 (6.5)9,759 (19.8)0.40
 >8 [65]730 (21.4)22,595 (45.9)0.54
 Unknown2,283 (66.9)13,009 (26.5)0.89
Duration of treated diabetes (years)0.3 (0.9)1.3 (2.0)0.64
Comedications
 Statins409 (12.0)24,898 (50.6)0.92
 Aspirin590 (17.3)17,635 (35.9)0.43
 Other NSAIDs537 (15.7)5,635 (11.5)0.13
Use of other antidiabetic drugs*
 Metformin547 (16.0)26,427 (53.7)0.86
 First-generation sulfonylureas39 (1.1)378 (0.8)0.04
 Thiazolidinediones28 (0.8)2,628 (5.3)0.26
 Incretin-based drugs0 (0.0)1,084 (2.2)0.21
 Insulin1 (0.0)117 (0.2)0.06
 Other oral hypoglycemic drugs18 (0.5)357 (0.7)0.03
  • Data are n (%) or mean (SD) unless otherwise indicated. IQR, interquartile range; NSAID, nonsteroidal anti-inflammatory drug.

  • *Not mutually exclusive.